HIV Vaccine Development Strategies
•Transferir como PPT, PDF•
16 gostaram•5,151 visualizações
This document summarizes different strategies for developing an HIV vaccine, outlining the challenges and current state of different vaccine types. It discusses how vaccines could potentially prevent or treat HIV infection, and highlights the obstacles like HIV's ability to mutate and target immune cells. Different vaccine types currently in clinical trials are described, including peptides, DNA, live vectors, and recombinant proteins. The largest vaccine trial to date, AIDSVAX, is summarized as stimulating antibodies but not proving effective against HIV.
![What is a vaccine? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Source: http://www.niaid.nih.gov/publications/pdf/HIVvaccinebrochure.pdf](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recomendados
Mais conteúdo relacionado
Mais procurados
Mais procurados (20)
Destaque
Destaque (20)
Semelhante a HIV Vaccine Development Strategies
Semelhante a HIV Vaccine Development Strategies (20)
Mais de Brian Wells, MD, MS, MPH
Mais de Brian Wells, MD, MS, MPH (20)
Último
Último (20)
HIV Vaccine Development Strategies
- 1. HIV Vaccine Development Strategies Brian Wells University of Florida October 15, 2003
- 17. Questions?
Notas do Editor
- The goal is to develop a vaccine that is 100 percent effective and protects everyone from infection. However, even if a vaccine only protects some people, it could have a major impact on controlling the epidemic. A partially effective vaccine could decrease the number of people who get infected with HIV; those people, in turn, would not pass the virus on to others. Even when an HIV vaccine is developed, education and other prevention efforts will be needed so that people continue to practice safe behaviors
- An ideal HIV vaccine should be able to elicit an immune response that recruits the appropriate effector mechanisms in order to render the organism resistant to infection. Cytotoxic T lymphocytes (CTLs), are an integral part of such a response, and thus, the development of vaccines capable of inducing strong, sustained, polyclonal, cross-reactive CTLs is a primary goal in HIV vaccine development.
- Ebola DNA vaccine works in Monkeys DNA vaccination, perhaps more precisely called DNA-mediated immunization, refers to the direct introduction by needle injection or particle bombardment into host organism tissues of a plasmid DNA (or an RNA) which is able to cause expression of an antigenic protein directly within the transfected cells. In this sense, DNA vaccination resembles a viral infection, since the biosynthetic machinery of the host is used for protein synthesis. This may result in secondary modifications of the synthesized antigen
- Harmless bacteria engineered to carry genes encoding HIV proteins
- Non-HIV viruses engineered to carry genes encoding HIV proteins; do not replicate completely